Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes

Chittaranjan Andrade1,2

  • 1Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India; Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.

PubMed

Insights

Pregnancy exposure to pregabalin is not linked to major birth defects or adverse outcomes like stillbirth or preterm birth. Further research is needed due to small sample sizes in pregabalin pregnancy studies.

Area of Science:

  • Pharmacology
  • Obstetrics and Gynecology
  • Developmental Pediatrics

Background:

  • Pregabalin, a gabapentinoid, functions by inhibiting calcium influx via the α2δ-1 subunit of voltage-gated calcium channels.
  • Its approved indications include neuropathic pain, fibromyalgia, seizures, and anxiety disorder, with off-label uses for various other conditions.
  • A small percentage of pregnant women may use pregabalin, necessitating an examination of pregnancy outcomes.

Purpose of the Study:

  • To evaluate the safety of pregabalin use during pregnancy.
  • To assess the association between gestational pregabalin exposure and major congenital malformations.
  • To investigate the impact of pregabalin exposure on other significant birth outcomes and neurodevelopmental disorders.

Main Methods:

  • A meta-analysis of 7 cohort studies was conducted.
  • Data from studies examining pregabalin-exposed pregnancies were synthesized.
  • Statistical analyses, including adjusted and unadjusted models, were employed to assess risks.

Main Results:

  • Pregabalin exposure in pregnancy was not associated with an increased risk of major congenital malformations.
  • Significant risks for outcomes like stillbirth, low birth weight, and preterm birth were generally not observed after adjustment for confounders.
  • While some studies indicated potential risks for attention-deficit/hyperactivity disorder and autism spectrum disorder, these were often not significant after adjustment.

Conclusions:

  • Gestational exposure to pregabalin does not appear to increase the risk of major congenital malformations.
  • Overall, pregabalin use in pregnancy is not linked to significant adverse birth outcomes when adjusted for confounding factors.
  • Limitations include small sample sizes in pregabalin-exposed pregnancy cohorts, warranting cautious interpretation and further investigation.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
620
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804
Neurulation01:30

Neurulation

Neurulation is the embryological process which forms the precursors of the central nervous system and occurs after gastrulation has established the three primary cell layers of the embryo: ectoderm, mesoderm, and endoderm. In humans, the majority of this system is formed via primary neurulation, in which the central portion of the ectoderm—originally appearing as a flat sheet of cells—folds upwards and inwards, sealing off to form a hollow neural tube. As development proceeds, the...
45.2K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
880